A persistent dry cough that develops while you’re taking methotrexate is not something to manage on your own. It can be a sign of drug-induced lung inflammation called methotrexate pneumonitis, and the most important step is stopping the medication, which requires coordination with your prescribing doctor. The good news: once recognized and treated promptly, methotrexate pneumonitis usually resolves fully and does not progress to permanent lung scarring.
Why Methotrexate Causes a Cough
Methotrexate can irritate and inflame the lungs through two main pathways. The first, and most supported by evidence, is a hypersensitivity reaction, essentially an allergic-type response where your immune system overreacts to the drug and attacks the delicate air sacs in your lungs. The second is direct toxicity, where methotrexate damages the thin walls of those air sacs on its own.
Either pathway produces similar symptoms: a dry, nonproductive cough that worsens over days to weeks, shortness of breath, and sometimes fever. Because methotrexate also suppresses your immune system, it can make you vulnerable to respiratory infections that cause similar symptoms, which is part of what makes the cough tricky to diagnose.
How to Tell It Apart From a Cold or Chest Infection
Not every cough on methotrexate is drug-related. Respiratory infections, lung changes from rheumatoid arthritis itself (called RA-ILD), and even other medications can all cause coughing. Several features help distinguish methotrexate pneumonitis from these other causes:
- Onset: Methotrexate pneumonitis tends to come on acutely or over a few weeks, not gradually over months. A very slow, creeping cough is more typical of lung disease from rheumatoid arthritis itself.
- Cough type: The cough is usually dry rather than producing thick or colored mucus. A productive cough with green or yellow sputum points more toward infection.
- Fever: Fever is common with methotrexate pneumonitis, but it’s also common with infections. Fever is rare with RA-related lung disease, so its presence helps narrow things down.
- Response to stopping the drug: The hallmark of methotrexate pneumonitis is significant improvement after the drug is discontinued. If your cough doesn’t improve after stopping, other causes become more likely.
Because there is no single definitive test, methotrexate pneumonitis is a diagnosis of exclusion. Your doctor will typically order chest imaging and blood work and may refer you for a procedure to examine the airways and rule out infections like Pneumocystis pneumonia, which can look almost identical on a scan.
What Stopping the Cough Actually Involves
There is no cough suppressant or home remedy that addresses the root problem. The cough is a symptom of lung inflammation, and treating it means treating that inflammation. The standard approach has two parts.
First, methotrexate is discontinued. Do not stop the drug abruptly on your own without telling your rheumatologist or prescriber, because your underlying condition (whether rheumatoid arthritis, psoriasis, or another disease) will need an alternative treatment plan. But stopping the drug is the single most critical step, and in mild cases, it may be all that’s needed.
Second, for moderate to severe cases, a course of corticosteroids is prescribed to calm the immune reaction in the lungs. Most people experience noticeable improvement within days to weeks of stopping methotrexate and starting steroid treatment. The long-term outlook is favorable: the inflammation typically resolves completely and does not lead to permanent lung fibrosis when caught and treated promptly.
Who Is Most at Risk
Methotrexate pneumonitis can happen to anyone on the drug, but certain factors raise the odds significantly. A multicenter case-control study identified the strongest predictors:
- Older age: Patients over 60 had roughly five times the risk compared to younger patients.
- Diabetes: This was the single strongest individual risk factor in the study, with dramatically elevated odds.
- Pre-existing lung involvement from rheumatoid arthritis: Having prior pleuropulmonary disease raised the risk about sevenfold.
- Low albumin levels: Hypoalbuminemia, which can reflect poor nutrition or chronic inflammation, was associated with roughly 20 times the risk.
- Previous use of other disease-modifying drugs: Having cycled through other medications before methotrexate also increased risk, about fivefold.
Other proposed risk factors include chronic kidney disease (which slows the drug’s clearance from your body), male sex, and pre-existing lung disease of any kind. If you fall into several of these categories and develop a new cough, it warrants prompt attention.
Symptoms That Need Urgent Attention
A mild, occasional cough that comes and goes may not be methotrexate pneumonitis. But certain combinations of symptoms suggest your lungs are actively inflamed and need evaluation soon rather than at your next scheduled appointment:
- A dry cough that is worsening over days rather than improving
- Shortness of breath with activities that didn’t previously cause it
- Fever, especially if you don’t have obvious signs of a cold or flu
- Feeling winded at rest or noticing your oxygen levels dropping below 90% if you have a pulse oximeter at home
An oxygen saturation below 90% on room air is one of the clinical markers used to assess severity. If you’re experiencing breathlessness significant enough to limit your normal activities, that warrants same-day medical evaluation.
What Comes Next for Your Treatment
Once methotrexate is off the table, you and your doctor will need an alternative medication for your underlying condition. Methotrexate is not restarted after a confirmed episode of pneumonitis, because rechallenge carries a high risk of recurrence.
Several other disease-modifying drugs are available depending on your diagnosis. For rheumatoid arthritis, options include other conventional medications as well as biologic therapies that work through different mechanisms than methotrexate. Your rheumatologist will factor in which drugs you’ve used before, your other health conditions, and the severity of your disease when recommending an alternative. The transition can take some planning, so the sooner the conversation happens, the less likely you are to experience a flare of your underlying condition during the switch.
At follow-up, typically around six months, most patients show full recovery on imaging and have no residual symptoms. The key variable in outcomes is how quickly the problem was recognized. A cough that’s been dismissed for months gives the inflammation more time to cause damage, while one caught early almost always resolves without lasting effects.